Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 20191,2 and is responsible for the coronavirus disease 2019 (COVID-19) pandemic3. Vaccines are an essential countermeasure and are urgently needed to control the pandemic4. Here we show that the adenovirus-vector-based vaccine ChAdOx1 nCoV-19, which encodes the spike protein of SARS-CoV-2, is immunogenic in mice and elicites a robust humoral and cell-mediated response. This response was predominantly mediated by type-1 T helper cells, as demonstrated by the profiling of the IgG subclass and the expression of cytokines. Vaccination with ChAdOx1 nCoV-19 (using either a prime-only or a prime–boost regimen) induced a balanced humoral and cellular immune response of type-1 and type-2 T helper cells in rhesus macaques. We observed a significantly reduced viral load in the bronchoalveolar lavage fluid and lower respiratory tract tissue of vaccinated rhesus macaques that were challenged with SARS-CoV-2 compared with control animals, and no pneumonia was observed in vaccinated SARS-CoV-2-infected animals. However, there was no difference in nasal shedding between vaccinated and control SARS-CoV-2-infected macaques. Notably, we found no evidence of immune-enhanced disease after viral challenge in vaccinated SARS-CoV-2-infected animals. The safety, immunogenicity and efficacy profiles of ChAdOx1 nCoV-19 against symptomatic PCR-positive COVID-19 disease will now be assessed in randomized controlled clinical trials in humans.
ChAdOx1 is a replication-deficient simian adenoviral vector derived from isolate Y25. The seroprevalence of antibodies against Y25 in the human population was found to be 0% of tested individuals in the UK and 9% in The Gambia5. It was previously demonstrated that a single dose of ChAdOx1 MERS, which encodes the spike protein of Middle East respiratory syndrome coronavirus (MERS-CoV), protected non-human primates (NHPs) against MERS-CoV-induced disease6. After the emergence of SARS-CoV-2, we designed a similar ChAdOx1-vector-based vaccine that encodes the codon-optimized full-length spike protein of SARS-CoV-2.
Immunogenicity in mice
Two mouse strains (BALB/c (n = 5) and outbred CD1 (n = 8)) were vaccinated intramuscularly with ChAdOx1 nCoV-19 or ChAdOx1 GFP—a control vaccine that encodes green fluorescent protein (GFP). Humoral and cellular immunity responses were studied 9–14 days later. Total IgG titres were detected against the spike protein in all of the vaccinated mice (Fig. 1a). Profiling of the IgG subclasses showed a predominantly type-1 T helper cell (TH1) response after vaccination (Extended Data Fig. 1a) and induction of IgM antibodies (Extended Data Fig. 2a). Virus-specific neutralizing antibodies were detected in all mice vaccinated with ChAdOx1 nCoV-19, whereas no neutralization was detected in serum from mice vaccinated with ChAdOx1 GFP (Fig. 1b). Splenic T cell responses measured by IFNγ ELISpot and intracellular cytokine staining were detected against peptides spanning the full length of the spike construct (Fig. 1c). Again, a strong TH1-type response was detected after vaccination as supported by high expression levels of IFNγ and TNF, and low expression levels of IL-4 and IL-10 (Fig. 1d and Extended Data Fig. 1b, c).
Immunogenicity in rhesus macaques
We next evaluated the efficacy of ChAdOx1 nCoV-19 in rhesus macaques, a NHP model that displays robust infection of the upper and lower respiratory tract and virus shedding after inoculation with SARS-CoV-27. Six animals per group were vaccinated using a prime-only regimen (28 days before challenge) or a prime–boost regimen (56 and 28 days before challenge) intramuscularly with 2.5 × 1010 ChAdOx1 nCoV-19 virus particles each. As a control, six animals were vaccinated via the same route with the same dose of ChAdOx1 GFP (one animal was vaccinated 56 and 28 days before challenge and five animals were vaccinated 28 days before challenge) (Fig. 2a). No adverse events were observed after vaccination. Spike-specific antibodies were present as early as 14 days after vaccination and were significantly increased after the second immunization (two-tailed signed-rank Wilcoxon test). Endpoint IgG titres of 400–6,400 (prime) and 400–19,200 (prime–boost) were measured on the day of challenge (Fig. 2b). Virus-specific neutralizing antibodies were also significantly increased after secondary immunization (two-tailed signed-rank Wilcoxon test) and detectable in all vaccinated animals before challenge (5–40 (prime) and 10–160 (prime–boost)), whereas no virus-specific neutralizing antibodies were detected in control animals (Fig. 2c). IgM antibodies were present in the serum after vaccination on the day of the challenge in six out of six prime–boost and two out of six prime-only animals (Extended Data Fig. 2b). SARS-CoV-2 spike-specific T cell responses were detected on the day of challenge by IFNγ ELISpot assay after the stimulation of peripheral blood mononuclear cells with a peptide library that spanned the full length of the spike protein. No statistically significant difference in the magnitude of the response was found between the prime–boost and prime-only group (Mann–Whitney U-test, P = 0.3723) (Fig. 2d). As previously reported6, vaccination with ChAdOx1 nCoV-19 resulted in the induction of neutralizing antibodies against the vaccine vector itself within 28 days of vaccination (Extended Data Fig. 3). Nonetheless, a boost vaccination with ChAdOx1 nCoV-19 resulted in a significant increase in binding and neutralizing antibodies in NHPs (Fig. 2b, c) and an increase in the SARS-CoV-2 virus-neutralizing titre was not significantly correlated with the ChAdOx1 virus-neutralizing titre (two-tailed Pearson correlation, r2 = 0.6493 P = 0.0529).
After challenge with a 50% tissue culture infective dose (TCID50) of 2.6 × 106 of SARS-CoV-2 in both the upper and lower respiratory tracts of rhesus macaques, the average clinical score of control animals was higher compared with ChAdOx1 nCoV-19-vaccinated animals. This was significantly different as determined using a Mann–Whitney U-test on 4–7 days post-infection (d.p.i.) (Fig. 3a).
Viral load in respiratory tract samples
In BAL fluid obtained from control animals, viral genomic RNA (gRNA) and subgenomic RNA (sgRNA), the latter of which is indicative of virus replication, were detected on all days. By contrast, viral gRNA and sgRNA were detected in only two vaccinated animals on 3 d.p.i., and the viral load was significantly lower (Fig. 3b). Viral gRNA was detected in nose swabs from all animals and no difference was found on any day between vaccinated and control animals. Viral sgRNA was detected in a minority of samples, with no difference between groups (Fig. 3c). Infectious virus could only be detected at 1 and 3 d.p.i. in prime-only vaccinated and control animals, and 1 d.p.i. in prime–boost vaccinated animals (Extended Data Table 1).
Cytokines in serum were analysed after challenge to monitor immune responses. After vaccination, the levels of TH1 (IFNγ and IL-2) or type-2 T helper cell (TH2) (IL-4, IL-5 or IL-13) cytokines in the serum of NHPs were low and no evidence of a dominant TH2 response was detected (Extended Data Fig. 4). We observed a significant upregulation in IFNγ at 1 d.p.i. in ChAdOx1 nCoV-19 prime-only-vaccinated animals, but not in prime–boost-vaccinated or control animals. IL-10 and IL-13 were significantly upregulated in control animals compared with prime–boost-vaccinated animals on 1 and 7 d.p.i. (IL-13 only), but not compared with prime-only-vaccinated animals. No significant differences were observed between ChAdOx1 nCoV-19-treated and control animals for TNF, IL-2, IL-4, IL-5 and IL-6 (Extended Data Fig. 4); this is consistent with a previously observed lack of upregulation of cytokines and chemokines in rhesus macaques after infection with SARS-CoV-2.
Pulmonary pathology and viral load
At 7 d.p.i., all animals were euthanized, and tissues were collected. None of the vaccinated monkeys developed pulmonary pathology after inoculation with SARS-CoV-2. All lungs were histologically normal and no evidence of viral pneumonia nor immune-enhanced inflammatory disease was observed. In addition, no SARS-CoV-2 antigen was detected by immunohistochemistry in the lungs of any of the vaccinated animals. Three out of six control animals developed some degree of viral interstitial pneumonia. Lesions were widely separated and characterized by thickening of alveolar septae by small amounts of oedema fluid and few macrophages and lymphocytes. Alveoli contained small numbers of pulmonary macrophages and, rarely, oedema. Type-II pneumocyte hyperplasia was observed. Multifocal, perivascular infiltrates of small numbers of lymphocytes that formed perivascular cuffs were observed. Immunohistochemistry analysis showed the presence of viral antigen in type-I and II pneumocytes, as well as in alveolar macrophages, in five out of six control animals (Fig. 4). We were unable to detect any lesions or immunohistochemistry-positive cells in nasal mucosa in any of the animals.
The viral gRNA load was high in the lung tissues of all control animals and viral sgRNA was detected in five out of six control animals (Fig. 3d). In the prime-only-vaccinated group, the viral gRNA load was significantly lower in lung tissues as determined using a Mann–Whitney’s U-test, and below the limit of detection in two out of six vaccinated animals; viral sgRNA was detected only in the lung tissue of one animal (Fig. 3d and Extended Data Fig. 5). In the prime–boost-vaccinated group, viral gRNA was detected in two out of six animals; one animal was weakly positive in one lung lobe and one animal, which mounted a limited response to vaccination, was positive in four lung lobes. Viral sgRNA could only be detected in lung tissue from the animal with a lower immune response (Fig. 3d and Extended Data Fig. 5). We did not detect infectious virus in any lung tissue.
Extrapulmonary pathology and viral load
No lesions were observed in gastrointestinal tissues of any animals. As previously reported7, SARS-CoV-2 antigen could be detected in lymphocytes and macrophages in the lamina propria of the intestinal tract of all control animals. This phenomenon was also observed in six out of six prime-only-vaccinated animals and three out of six prime–boost-vaccinated animals. There were no histological differences between lymphoid tissues of vaccinated or control animals.
Viral gRNA could be detected in extrarespiratory tissues but was predominantly low in all animals and not associated with the detection of sgRNA. The viral gRNA load in intestinal tissues of prime–boost-vaccinated animals was higher than the levels measured in control and prime-only-vaccinated animals and was associated with the detection of sgRNA. However, no infection of intestinal tissue was observed by immunohistochemistry, nor were we able to detect infectious virus in intestinal tissue (Extended Data Fig. 6).
Here we show that a single vaccination with ChAdOx1 nCoV-19 is effective in preventing damage to the lungs after challenging NHPs with a high dose of SARS-CoV-2 to both upper and lower respiratory tract, and a prime–boost regimen significantly increased humoral immune responses. We did not observe an increase in cellular responses after a second dose of ChAdOx1 nCoV-19, in line with results reported in a previously published study, in which a homologous prime–boost regimen with malaria vaccine candidate ChAd63 ME-TRAP was used8. A small decrease in spike- and vector-specific antibody titres was observed between 14 days before challenge and the day of challenge in the prime–boost group. Longitudinal preclinical and clinical studies will investigate whether this decline in antibody titre is significant over time.
Two recently published SARS-CoV-2 vaccine studies in NHPs showed similar results: the first used a three-dose vaccination regimen of a high dose of whole inactivated SARS-CoV-2, which protected rhesus macaques from SARS-CoV-2 pneumonia9; and the second used a two-dose vaccination regimen with a DNA vaccine that encodes the spike protein, which significantly reduced viral RNA presence in BAL fluid and nasal swabs10. These three studies were conducted at different locations using different protocols, and therefore a direct comparison is difficult. Animals were challenged with 1 × 106 TCID50 by the intratracheal route9, with 1.1 × 104 plaque-forming units via the intratracheal and intranasal route10 or, in this study, with 2.6 × 106 TCID50 via intratracheal, intranasal, ocular and oral routes. The virus-neutralizing titres induced in vaccinated animals were similar between studies; vaccination with 2 doses of ChAdOx1 nCoV-19 resulted in a median virus-neutralizing titre of 80 determined in an inhibitory concentration (IC)100 assay. In other studies, 3 doses of 6 μg inactivated SARS-CoV-2 and 2 doses of spike-encoding DNA resulted in median virus-neutralizing titres of 50 and 74, respectively, measured in an IC50 assay. A priming vaccination with ChAdOx1 nCoV-19 resulted in virus-neutralizing titres similar to those obtained after inoculation of rhesus macaques with SARS-CoV-27. After vaccination with one or two doses of ChAdOx1 nCoV-19, the viral loads in BAL fluid and lung tissue of vaccinated animals were significantly reduced, which suggests that vaccination prevents or strongly reduces virus replication in the lower respiratory tract. Despite this marked difference in virus replication in the lungs, we did not observe a reduction in viral shedding from the nose in either the prime-only or prime–boost regimen. Notably, viral RNA in nose swabs from vaccinated animals was also detected in one study10, whereas the other study9 challenged only the lower respiratory tract with SARS-CoV-2 and therefore did not assess nasal shedding.
Our primary goal for a vaccine against SARS-CoV-2 is to prevent disease, and we did not observe pneumonia or viral antigen in the lungs of vaccinated animals. On the basis of the data presented here, it is possible that a single or double dose of ChAdOx1 nCoV-19 will not prevent infection with or transmission of SARS-CoV-2. However, it could significantly reduce illness. Animals in this study were challenged with a high dose of virus using multiple routes as a stringent test of the protective efficacy of the vaccine and the absence of enhanced disease after infection. This does not reflect a realistic human exposure with regard to the route and dose. Future studies will determine whether changing the route of vaccination to expose mucosal surfaces will induce mucosal immunity, which may result in reduced nasal shedding and onward transmission. It should be noted that detection of sgRNA in nasal swabs was low with lower levels also detected in intestinal tissues. No viral antigen could be detected by immunohistochemistry, and it is not yet clear whether the virus is replicating in the nasal mucosa of vaccinated animals.
Several preclinical studies of vaccines against SARS-CoV resulted in immunopathology after vaccination and subsequent challenge, with more severe disease in vaccinated animals than in controls11,12,13,14,15. Immune-enhanced disease could be observed as early as 2 d.p.i. in mice14,15 and 7 d.p.i. in NHPs13. Immune-enhanced disease was associated with a TH2 response in mice14 and diffuse alveolar damage and cellular infiltrates in NHPs13. In this study, there was no evidence of immune-enhanced disease in vaccinated animals. The immune response was not skewed towards a TH2 response in mice or NHPs, there was no increase in clinical signs or virus replication throughout the study in vaccinated NHPs compared to controls and no markers of disease enhancement in pulmonary tissue of NHPs, such as an influx of cells or diffuse alveolar damage, were observed. The clinical scores of vaccinated animals were lower than the clinical scores in control animals, which strongly suggests that immune-enhanced disease was absent.
Results from ongoing clinical trials will be the most informative in determining whether ChAdOx1 nCoV-19 will be an appropriate vaccine candidate, but the results described in the present study are encouraging. The data presented here informed the start of a phase I clinical trial with ChAdOx1 nCoV-19 on 23 April 2020. As of 1 July 2020, more than 8,000 volunteers have participated in the randomized controlled clinical trials. This study is therefore an important step towards the development of a safe and efficacious SARS-CoV-2 vaccine.
Mice were used in accordance with the UK Animals (Scientific Procedures) Act under project licence number P9804B4F1 granted by the UK Home Office. Animals were housed in groups in individually ventilated cages under specific-pathogen-free conditions, at a constant temperature (20–24 °C) and humidity (45–65%) with lighting on a fixed light/dark cycle (12-h/12-h).
Approval for experiments involving NHPs was provided by the Institutional Animal Care and Use Committee (IACUC) at Rocky Mountain Laboratories. Animal experiments were carried out in an Association for Assessment and Accreditation of Laboratory Animal Care (AALAC)-approved facility by certified staff, following the basic principles and guidelines in the NIH Guide for the Care and Use of Laboratory Animals, the Animal Welfare Act, US Department of Agriculture and the US Public Health Service Policy on Humane Care and Use of Laboratory Animals. Rhesus macaques were housed in individual primate cages that enabled social interactions in a climate-controlled room with a fixed light/dark cycle (12-h/12-h) and were monitored at least twice daily. Commercial monkey chow, treats and fruit were provided by trained personnel. Water was available ad libitum. Environmental enrichment consisted of a variety of human interactions, commercial toys, videos and music. The Institutional Biosafety Committee (IBC) approved work with infectious SARS-CoV-2 virus strains under BSL3 conditions. Virus inactivation of all samples was performed according to IBC-approved standard operating procedures for the removal of specimens from high containment areas.
Generation of vaccine ChAdOx1 nCoV-19
The spike protein of SARS-CoV-2 (GenBank accession number YP_009724390.1)—the surface glycoprotein responsible for receptor binding, fusion and entry into the host cell—was codon-optimized for expression in human cell lines and synthesized with the tissue plasminogen activator (tPA) leader sequence at the 5′ end by GeneArt Gene Synthesis (Thermo Fisher Scientific). The sequence, which encodes amino acids 2–1273 of SARS-CoV-2 and the tPA leader, was cloned into a shuttle plasmid using InFusion cloning (Clontech). The shuttle plasmid encodes a modified human cytomegalovirus major immediate early promoter with tetracycline operator sites and a poly-adenylation signal from bovine growth hormone between Gateway recombination cloning sites. ChAdOx1 nCoV-19 was prepared using Gateway recombination technology (Thermo Fisher Scientific) between the shuttle plasmid described and the previously described ChAdOx1 destination DNA BAC vector5, resulting in the insertion of the SARS-CoV-2 expression cassette at the E1 locus. The ChAdOx1 adenovirus genome was excised from the BAC using unique PmeI sites flanking the adenovirus genome sequence. The virus was rescued and propagated in T-Rex HEK293 cells (Invitrogen) in which antigen expression during virus propagation is repressed. Purification was carried out using CsCl gradient ultracentrifugation. Virus titres were determined by hexon immunostaining assay and viral particles were calculated on the basis of spectrophotometry16,17.
Study design of animal experiments
Female BALB/cOlaHsd (BALB/c) (Envigo) and outbred Crl:CD1(ICR) (CD1) (Charles River) mice of at least 6 weeks of age, were immunized by intramuscular injection in the musculus tibialis with 6 × 109 virus particles of ChAdOx1 nCoV-19 unless otherwise stated.
Adult rhesus macaques (17 male and 1 female) between 2 and 4 years old were randomly divided into three groups of six animals. Animal group size was based on initial model development. Group 1 was vaccinated with ChAdOx1 nCoV-19 at −28 d.p.i., group 2 was vaccinated with ChAdOx1 nCoV-19 at −56 and −28 d.p.i., group 3 was vaccinated with ChAdOx1 GFP at −56 and −28 d.p.i. (1 animal) or at −28 d.p.i. (5 animals). All vaccinations were done with 2.5 × 1010 virus particles per animal diluted in sterile PBS. Blood samples were obtained before vaccination and 14 days afterwards. Animals were challenged with SARS-CoV-2 strain nCoV-WA1-2020 (MN985325.1) diluted in sterile DMEM on day 0; with administration of 4 ml intratracheally, 1 ml intranasally, 1 ml orally and 0.5 ml ocularly of 4 × 105 TCID50 ml−1 virus suspension. Animals were scored daily by the same person, who was blinded to study group allocations using a standardized scoring sheet. Scoring was based on the following criteria: general appearance, appearance of the skin and coat, discharge, respiration, appearance of the faeces and urine, appetite and activity. The scoring sheet can be found in a previously published study7. Clinical examinations were performed on −28, −14, 0, 1, 3, 5 and 7 d.p.i. Nasal swabs and blood were collected on all days that examinations were performed. BAL was obtained on 3, 5 and 7 d.p.i. by insertion of an endotracheal tube and bronchoscope into the trachea, then past the third bifurcation and subsequent addition of 10 ml of sterile saline. Manual suction was applied to retrieve the BAL sample. Serum biochemistry (albumin, aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transferase, blood urea nitrogen and creatinine) was analysed using the Vetscan VS2 Chemistry Analyzer and VetScan 2 Preventative Care 12 discs (Abaxis) (Supplementary Tables 1–3). Necropsy was performed on 7 d.p.i. and the following tissues were collected: cervical lymph node, mediastinal lymph node, conjunctiva, nasal mucosa, oropharynx, tonsil, trachea, all six lung lobes, right and left bronchus, heart, liver, spleen, kidney, stomach, duodenum, jejunum, ileum, caecum, colon and urinary bladder.
Cells and virus
SARS-CoV-2 strain nCoV-WA1-2020 (MN985325.1) was provided by the CDC. Virus propagation was performed in Vero E6 cells in DMEM supplemented with 2% fetal bovine serum (FBS), 1 mM l-glutamine, 50 U ml−1 penicillin and 50 μg ml−1 streptomycin. The used virus stock was 100% identical to the initial deposited GenBank sequence (MN985325.1) and no contaminants were detected. Vero E6 cells were maintained in DMEM supplemented with 10% FBS, 1 mM l-glutamine, 50 U ml−1 penicillin and 50 μg ml−1 streptomycin. Vero E6 cells were provided by R. Baric and were not authenticated in-house; mycoplasma testing was performed at regular intervals and no mycoplasma was been detected.
Virus isolation from tissue
Tissue sections were weighed and homogenized in 1 ml of DMEM. Then, 250 μl of homogenate was added to Vero E6 cells in a 24-well plate in duplicate. After 1 h at 37 °C and 5% CO2, cells were washed with PBS and 500 μl of DMEM containing 2% FBS was added. Cells were incubated at 37 °C and 5% CO2. Cytopathogenic effects were assessed 6 days later.
Virus neutralization assay for SARS-CoV-2
Sera were heat-inactivated (30 min, 56 °C), twofold serial dilutions were prepared in 2% DMEM and 100 TCID50 of SARS-CoV-2 was added. After 1 h incubation at 37 °C and 5% CO2, the virus:serum mixture was added to Vero E6 cells and incubated at 37 °C and 5% CO2. At 5 d.p.i., cytopathogenic effects were assessed. The virus neutralization titre was expressed as the reciprocal value of the highest dilution of the serum that still inhibited virus replication.
Virus neutralization assay using ChAdOx1
Chimpanzee adenovirus ChAdOx1-specific neutralizing antibody titres were assessed using a secreted placental alkaline phosphatase (SEAP) quantification assay as previously described6. In brief, GripTite MSR 293 cells (Invitrogen, R795-07) were infected with serially diluted serum in phenol-red-free DMEM (Life Technologies, 31053028) and the ChAdOx1-SEAP reporter virus in a 1:1 mixture for 1 h before replacing with phenol-red-free DMEM containing 10% FBS for 24 h. For each sample, the SEAP concentration was assessed in 50-μl aliquots of culture supernatant, with CPSD as an indicator substrate (Tropix Phospha-Light Chemiluminescent Assay Kit, Life Technologies, T1017). Luminescence intensity was measured using a Varioskan Flash luminometer (Thermo Fisher Scientific). Serum dilution neutralization titres were measured by linear interpolation of adjacent values (to 50% inhibition) to determine the serum dilution required to reduce the SEAP concentration by 50% compared to wells with virus alone.
RNA extraction and quantitative reverse-transcription polymerase chain reaction
Tissues (up to 30 mg) were homogenized in RLT buffer and RNA was extracted using the RNeasy kit (Qiagen) according to the manufacturer’s instructions. RNA was extracted from BAL fluid and nasal swabs using the QiaAmp Viral RNA kit (Qiagen) according to the manufacturer’s instructions. Viral gRNA-specific18 and sgRNA-specific19 assays were used for the detection of viral RNA. RNA (5 μl) was tested with the Rotor-Gene probe kit (Qiagen) according to the manufacturer’s instructions. Dilutions of SARS-CoV-2 standards with known genome copies were run in parallel.
ELISA of mouse sera
MaxiSorp plates (Nunc) were coated with S1 (monomeric, amino acids 1–674) or S2 (monomeric, amino acids 685–1211) (The Native Antigen Company; 50 ng per well) or with prefusion-stabilized SARS-CoV-2 spike protein (250 ng per well) in PBS for overnight adsorption at 4 °C. Plates were washed in PBS–Tween (0.05% v/v) and wells were blocked using casein (ThermoFisher Scientific) for 1 h at room temperature. Serially diluted mouse serum samples were added and incubated overnight at 4 °C or 37 °C for 2 h for specific IgM detection. Plates were washed and alkaline phosphatase-conjugated goat anti-mouse IgG (Sigma) or IgM (Abcam) was added to all wells for 1 h at room temperature or 2 h at 37 °C. After washing the plates, pNPP substrate (Sigma) was added. Optical density (OD) values for each well were measured at 405 nm. Endpoint titres were calculated as follows: the log10(OD) against log10(sample dilution) was plotted and a regression analysis of the linear part of this curve enabled calculation of the endpoint titre with an OD of three times the background. The same calculation was used to dilute the sera to the same amounts of total IgG for further testing on different IgG subclasses with anti-mouse IgG subclass-specific antibodies (Abcam). The results of the IgG subclass ELISA are presented using OD values.
ELISA of NHP sera
Prefusion-stabilized SARS-CoV-2 spike protein with a T4 fibritin trimerization motif20 was obtained from the Vaccine Research Centre. Maxisorp plates (Nunc) were coated overnight at 4 °C with 100 or 250 ng spike protein per well in PBS for IgG and IgM detection, respectively. Plates were blocked with 100 μl of casein in PBS (Thermo Fisher) for 1 h at room temperature. Serum serially diluted 2× in casein in PBS was incubated at room temperature for 1 h or 37 °C for 2 h. IgG antibodies were detected using affinity-purified polyclonal antibody peroxidase-labelled goat-anti-monkey IgG (Seracare, 074-11-021) in casein and TMB two-component peroxidase substrate (Seracare, 5120-0047), developed for 5–10 min and the reaction was stopped using stop solution (Seracare, 5150-0021) and read at 450 nm. IgM antibodies were detected using anti-monkey alkaline phosphatase-conjugated antibodies after adding the pNPP substrate and measuring OD values at 405 nm. All wells were washed 4× with PBST 0.1% Tween in between steps. The threshold for positivity was set at 3× the OD value of the negative control (serum obtained from NHPs before the start of the experiment) or 0.2, whichever was higher, or at 3× the OD of the background for the calculation of the IgM endpoint values.
ELISpot assay and intracellular cytokine staining analysis
Single-cell suspensions of mouse splenocytes were prepared by passing cells through 70-μm cell strainers and ACK lysis before resuspension in complete medium. Peripheral blood mononuclear cells (PBMCs) from rhesus macaques were isolated from ethylene diamine tetraaceticacid (EDTA) whole blood using Leucosep tubes (Greiner Bio-one International) and Histopaque-1077 density-gradient cell-separation medium (Sigma-Aldrich) according to the manufacturers’ instructions.
For analysis of IFNγ production by ELISpot, cells were stimulated with pools of S1 or S2 peptides (final concentration of 2 μg ml−1) on IPVH-membrane plates (Millipore) coated with 5 μg ml−1 anti-mouse IFNγ (AN18). After 18–20 h of stimulation, IFNγ spot-forming cells were detected by staining membranes with anti-mouse IFNγ–biotin (1 μg ml−1) (R46A2) followed by streptavidin–alkaline phosphatase (1 μg ml−1) and development with an alkaline phosphatase conjugate substrate kit (BioRad).
For analysis of intracellular cytokine production, cells were stimulated at 37 °C for 6 h with 2 μg ml−1 S1 or S2 pools of peptide, medium or a cell-stimulation cocktail (containing phorbol 12-myristate 13-acetate (PMA) and ionomycin, Biolegend), together with 1 μg ml−1 Golgi-plug (BD) with the addition of 2 μl ml−1 CD107a–Alexa647. The cell supernatant was collected and frozen at –20 °C for subsequent analysis using a MesoScale Discovery (MSD) assay (see below). After cell-surface staining with CD4–BUV496, CD8–PerCPCy5.5, CD62L–BV711, CD127–BV650 and LIVE/DEAD Aqua, cells were fixed with 4% paraformaldehyde and stained intracellularly with TNF–A488, IL-2–PECy7, IL-4–BV605, IL-10–PE and IFNγ–e450 diluted in Perm-Wash buffer (BD).
Sample acquisition was performed on a Fortessa (BD) and data were analysed in FlowJo V10 (TreeStar). An acquisition threshold was set at a minimum of 5,000 events in the live CD3+ gate. Antigen-specific T cells were identified by gating on LIVE/DEAD-negative, doublet-negative (FSC-H versus FSC-A), size (FSC-H versus SSC), CD3+, CD4+ or CD8+ cells and cytokine-positive (the gating strategy is shown in Supplementary Fig. 1). Cytokine-positive responses are presented after subtraction of the background response detected in the corresponding unstimulated sample (medium containing CD107a and Golgi-plug) of each individual spleen sample. To determine whether there were statistically significant differences in the levels of cytokines produced by CD4+ or CD8+ T cells, data in each graph were analysed using a two-way (repeated-measure) ANOVA and post hoc Tukey’s multiple comparison tests.
For the IFNγ ELISpot assay of PBMCs, cells were plated at a concentration of 100,000 cells per well and were stimulated with 4 contiguous peptide pools that spanned the length of the SARS-CoV-2 spike protein sequence at a concentration of 2 μg ml−1 per peptide (Mimotopes). The ImmunoSpot Human IFNγ Single-Colour Enzymatic ELISpot Assay Kit was performed according to the manufacturer’s protocol (Cellular Technology). ELISpot plates were inactivated in formalin overnight before removal from biosafety level 4 facilities for reading. Analysis was performed using the CTL ImmunoSpot Analyzer and ImmunoSpot Software (Cellular Technology). Spot-forming units per 1.0 × 106 PBMCs were summed across the four peptide pools for each animal.
Measurement of cytokines and chemokines
Mouse samples were assayed using the MSD Technology V-PLEX Mouse Cytokine 29-Plex kit according to the manufacturer’s instructions. The NHP samples were inactivated with γ-radiation (2 MRad) according to standard operating procedures and assayed on a Bio-Plex 200 instrument (Bio-Rad) using the Non-Human Primate Cytokine MILLIPLEX map 23-plex kit (Millipore) according to the manufacturer’s instructions. Lower limit of detection was used for all undetectable and extrapolated values. Only data for cytokines consistently above the lower limit of quantification were included in further analyses.
The log10-transformed fold change (log10(FC)) for mouse samples was calculated as follows: log10(FC) = log10[(stimulated (pg ml−1) + 1)/(unstimulated (pg ml−1) + 1)].
The fold change for NHP samples was calculated as follows (in which X = 1, 3, 5 or 7): FC = (concentration (pg ml−1) on day X)/(concentration (pg ml−1) on day 0).
Histology and immunohistochemistry
Necropsies and tissue sampling were performed according to IBC-approved protocols. Lungs were perfused with 10% formalin and processed for histological review. Collected tissues were fixed for 8 days in 10% neutral-buffered formalin, embedded in paraffin, processed using a VIP-6 Tissue Tek (Sakura Finetek) tissue processor, and embedded in Ultraffin paraffin polymer (Cancer Diagnostics). Samples were sectioned at 5 μm, and resulting slides were stained with haematoxylin and eosin. Specific anti-CoV immunoreactivity was detected using a SARS-CoV-2 nucleocapsid protein rabbit antibody (Genscript) at a 1:1,000 dilution. The immunohistochemistry assay was carried out on a Discovery ULTRA automated-staining instrument (Roche Tissue Diagnostics) with a Discovery ChromoMap DAB (Ventana Medical Systems) kit. All tissue slides were evaluated by a board-certified veterinary anatomic pathologist blinded to study group allocations. In total, 18 sections taken from 6 different lung lobes were evaluated per animal; a representative lesion from each group was selected for Fig. 4.
Two-tailed Mann–Whitney U-tests or signed-rank Wilcoxon tests were conducted to compare differences between groups using Graphpad Prism version 8.3.0. A Bonferroni correction was used to control for type-I errors where required.
Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data have been deposited in Figshare (https://figshare.com/articles/dataset/Figshare_document_xlsx/12290696).
Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020).
Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020).
WHO. Coronavirus disease (COVID-19) Situation Report 113. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200512-covid-19-sitrep-113.pdf?sfvrsn=feac3b6d_2 (2020).
Lurie, N., Saville, M., Hatchett, R. & Halton, J. Developing COVID-19 vaccines at pandemic speed. N. Engl. J. Med. 382, 1969–1973 (2020).
Dicks, M. D. et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE 7, e40385 (2012).
van Doremalen, N. et al. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. Sci. Adv. 6, eaba8399 (2020).
Munster, V. J. et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature https://doi.org/10.1038/s41586-020-2324-7 (2020).
Bliss, C. M. et al. Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. Sci. Rep. 8, 3390 (2018).
Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77–81 (2020).
Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806–811 (2020).
Weingartl, H. et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 78, 12672–12676 (2004).
Bolles, M. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85, 12201–12215 (2011).
Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4, e123158 (2019).
Tseng, C. T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 7, e35421 (2012).
Yasui, F. et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J. Immunol. 181, 6337–6348 (2008).
Bewig, B. & Schmidt, W. E. Accelerated titering of adenoviruses. Biotechniques 28, 870–873 (2000).
Maizel, J. V. Jr, White, D. O. & Scharff, M. D. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36, 115–125 (1968).
Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 25, 2000045 (2020).
Wölfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465–469 (2020).
Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
We thank O. Abiona, B. Bailes, A. Carmody, K. Corbett, K. Cordova, J. Faris, H. Feldmann, S. Gerber, B. Graham, E. Haddock, R. Kissinger, M. Jones, M. Marsh, K. Menk, A. Mora, S. Seifert, L. Shupert, B. Smith, N. Thornburg, A. Weidow, M. Woods and K. C. Yinda for their assistance during this study. This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) (1ZIAAI001179-01) and the Department of Health and Social Care using UK Aid funding managed by the NIHR.
S.C.G. is a board member of Vaccitech and named as an inventor on a patent covering the use of ChAdOx1-vector-based vaccines and a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). T.L. is named as an inventor on a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). The University of Oxford and Vaccitech, having joint rights in the vaccine, entered into a partnership with AstraZeneca in April 2020 for further development, large-scale manufacture and global supply of the vaccine. Equitable access to the vaccine is a key component of the partnership. Neither Oxford University nor Vaccitech will receive any royalties during the pandemic period or from any sales of the vaccine in developing countries. The other authors declare no competing interests.
Peer review information Nature thanks Wolfgang Baumgärtner and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data figures and tables
a, IgG subclass antibodies detected against S1 or S2 protein in sera of BALB/c or CD1 mice. b, Frequency of cytokine-positive CD3+ T cells after stimulation of splenocytes with S1-pool (solid colours) or S2-pool (transparent colours) peptides in BALB/c (red) and CD1 (blue) mice. c, The log10-transformed fold change in cytokine levels in supernatants from splenocytes stimulated with S1 (dark) or S2 (transparent) are shown in comparision to the corresponding unstimulated splenocyte samples for BALB/c and CD1 mice. a–c, n = 5 (BALB/c) and 8 (CD1) animals examined in a single independent experiment.
a, Spike-specific serum IgM in mice 14 days after vaccination. n = 5 (BALB/c) and 8 (CD1) mice examined in a single independent experiment. b, Spike-specific serum IgM in NHPs after prime–boost or prime-only vaccination. n = 6 animals per group examined in 2 independent experiments.
The control NHP treated with the prime–boost regimen is shown as an open triangle. VN, virus neutralizing. n = 6 animals per group examined in 2 independent experiments.
Fold increase in cytokines in serum compared to prechallenge values. **P < 0.01. the lines indicate the median. Statistical significance was determined by two-tailed Mann–Whitney U-test. P values for the different cytokines were: IFNγ, P = 0.0087; IL-10, P = 0.0043; IL-13, P = 0.0043 (left) and P = 0.0065 (right). n = 6 animals per group examined in 2 independent experiments.
Extended Data Fig. 5 Viral load in lung tissue of rhesus macaques challenged with SARS-CoV-2 at 7 d.p.i.
Viral gRNA (left) and sgRNA (right) in lung tissues.
Extended Data Fig. 6 Viral load in tissues of rhesus macaques challenged with SARS-CoV-2 at 7 d.p.i.
a, Viral gRNA in respiratory tissues excluding lung tissue. b, Viral gRNA in non-respiratory tissues. c, Viral sgRNA in respiratory tissues excluding lung tissue. d, Viral sgRNA in non-respiratory tissues.
About this article
Cite this article
van Doremalen, N., Lambe, T., Spencer, A. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 586, 578–582 (2020). https://doi.org/10.1038/s41586-020-2608-y
Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world
BMC Infectious Diseases (2022)
Beni-Suef University Journal of Basic and Applied Sciences (2022)
Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production
BMC Medicine (2022)
On the caveats of a multiplex test for SARS-CoV-2 to detect seroconversion after infection or vaccination
Scientific Reports (2022)
A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs
Cell Research (2022)